Pharma BD Deal Intelligence
FierceBiotech framed the deal as Novartis's entry into 'the frenzied race for PD-1 targeting therapies,' noting BMS, Merck and Roche had all generated…
Mark Fishman: Immunotherapy agents provide additional arrows in our quiver for such combinations. Article notes Merck, BMS and Roche were in a three-way race…
PMLiVE described the acquisition as Novartis's overdue entry into PD-1, observing the company had been notably absent from the checkpoint race despite leading…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novartis acquired Cambridge-based immuno-oncology biotech CoStim Pharmaceuticals for an undisclosed sum, gaining late-discovery checkpoint programs including PD-1 and the option to combine them with Novartis' CAR-T platform. Strategically notable as Novartis' formal entry into the PD-1 race alongside its CTL019/Kymriah work.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / CoStim Pharmaceuticals, Inc. (this deal) | 2014 | — | 26 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2014 deals · Novartis AG deals · Oncology deals